Teva, Eagle Sue Canadian Firm to Block Branded Cancer Generics
Pharmaceuticals

Teva, Eagle Sue Canadian Firm to Block Branded Cancer Generics

Staff Reporter 1187 Views 0 Comments

Two units of Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals Inc. filed a lawsuit alleging that a small Canadian company’s proposed branded generic versions of Bendeka and Treanda infringe 11 patents for the cancer drugs.

Eagle and the Teva subsidiaries—Teva Pharmaceuticals International GmbH and Cephalon LLC—sued Montreal-based BendaRx Corp. on May 4 in the US District Court for the District of Delaware.

The next day, they filed an amended complaint after lawyers for BendaRx Corp. in Canada said the company’s regulatory notice letter “contained an error and should have identified ‘BendaRx USA Corp.,’ not ‘BendaRx Corp.’ as the submitter” …

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply